The first affiliated hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
NCT Number: NCT06365580
This clinical trial is the first-in-human study of Kylo-0603. The purpose of this randomized, double-blind, placebo-controlled phase 1 study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and effect of food of Kylo-0603 in healthy Chinese adult subjects.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Hangzhou, Zhejiang, 310000, China
The study consists of three parts: single ascending doses (Part 1), food effect (Part 2) and multiple ascending doses (Part 3).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administrated orally.
Administrated orally.
Time frame: up to 3 weeks
Time frame: up to 3 weeks
Time frame: up to 3 weeks
Time frame: up to 3 weeks
Kylonova (Xiamen) Biopharma co., LTD.
Industry
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Doses of Kylo-0603 Capsules in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04801849
Digestive System Diseases, Fatty Liver
La Jolla, California, United States
View Trial DetailsNCT02815891
Digestive System Diseases, Fatty Liver
Phoenix, Arizona, United States
View Trial DetailsNCT05877547
Digestive System Diseases, Fatty Liver
Chandler, Arizona, United States
View Trial DetailsNCT04971785
Digestive System Diseases, Fatty Liver
Birmingham, Alabama, United States
View Trial Details